Drugs

PEER-REVIEWED FEATURE

Mosunetuzumab: Adis Evaluation

Clinical Considerations

- An anti-CD20/CD3 T-cell engaging bispecific antibody is being developed by Genentech, a member of the Roche Group, for the treatment of relapsed or refractory follicular lymphoma
- Received its first approval on 3 June 2022 in the EU
- Approved for use in adults with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies

Summary

Mosunetuzumab (Lunsumio®), an anti-CD20/CD3 T-cell engaging bispecific antibody, is being developed by Roche for the treatment of relapsed or refractory follicular lymphoma.

Mosunetuzumab was recently conditionally approved in the EU for the treatment of relapsed or refractory follicular lymphoma in adults who have received at least two prior systemic therapies.

This article summarizes the milestones in the development of mosunetuzumab leading to this first approval for relapsed or refractory follicular lymphoma.

Kang, C. Drugs. 2022. https://doi.org/10.1007/s40265-022-01749-5